Investors and Media

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture
(NASDAQ: SGMO) $6.05 - 0.43 (6.636%) High
Volume 1,030,344 4:00 PM ET on May 3, 2016 Delayed at least 20 minutes

Investor Presentation

Corporate Fact Sheet